To investigate if the increased rate of recurrence observed in Luminal B patients in the current study can be fully attributed to HER2 dependency and not NF-κB pathway activation, patients with Luminal B tumours were further divided into those with HER2 positive tumours or high Ki67. Here, ERBB2 is linked to neoplasm.